Related Experiment Videos
[A clinical study on imipenem/cilastatin sodium in the field of pediatrics]
Insights
Imipenem/cilastatin sodium (MK-0787/MK-0791) demonstrated high clinical and bacteriological efficacy in treating respiratory tract infections, urinary tract infections, and gastroenteritis. This antibiotic combination showed a 91% eradication rate with no observed side effects in 33 patients.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Microbiology
Context:
- Imipenem/cilastatin sodium (MK-0787/MK-0791) is a potent antibiotic combination.
- Evaluating novel antibiotic treatments is crucial for combating resistant bacterial infections.
Purpose:
- To assess the clinical effectiveness, bacteriological efficacy, and safety of imipenem/cilastatin sodium (MK-0787/MK-0791).
Summary:
- A clinical study evaluated MK-0787/MK-0791 in 33 patients with respiratory tract infections, urinary tract infections, and gastroenteritis.
- Clinical effectiveness was high across infection types, with 100% efficacy in cases with isolated causative organisms.
- Bacteriological efficacy showed a 91% eradication rate for Gram-positive cocci and Gram-negative bacilli, with no significant adverse reactions reported.
Impact:
- Imipenem/cilastatin sodium (MK-0787/MK-0791) exhibits strong antimicrobial activity and a favorable safety profile.
- This study supports the use of imipenem/cilastatin sodium for treating various bacterial infections.
- Further research may explore its role in managing antibiotic-resistant pathogens.
Abstract:
A clinical study on imipenem/cilastatin sodium (MK-0787/MK-0791) was carried out and the following results were obtained. MK-0787/MK-0791 was used for treatment of a total of 33 patients and clinical effectiveness, bacteriological efficacy and adverse reactions were evaluated. The clinical effects were excellent in 1 case, good in 21 cases and fair in 2 cases in a total of 24 cases with respiratory tract infections, were excellent in 5 cases and good in 1 case in a total of 6 cases with urinary tract infections, and were good in 2 cases and fair in 1 case in a total of 3 cases with gastroenteritis. Causative organisms isolated from 11 patients were 1 strain of Gram-positive cocci and 10 strains of Gram-negative bacilli. Ten out of 11 strains were eradicated for an eradication rate of 91%. The clinical efficacy was confirmed in 11 cases for an efficacy rate of 100%. The bacteriological study has shown that MK-0787/MK-0791 has a strong antimicrobial activity. No side effects were observed. There was only one abnormal laboratory finding, i.e., a case of eosinophilia.